ReviewUrolithiasis2016
Ascorbic acid intake and oxalate synthesis.
Review in Urolithiasis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 113 citations in OpenAlex.
- Metabolic origins of hyperoxaluria: the critical role of precursors and vitamin B6 status in rats.Urolithiasis · 2026Review
- Serum and urine metabolomic profiling in Miniature Schnauzer dogs with and without calcium oxalate urolithiasis.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Recurrent Severe Hyponatremia Following Polyethylene Glycol Electrolyte Lavage Solution with Ascorbic Acid in a Patient with Undiagnosed Syndrome of Inappropriate Antidiuretic Hormone Secretion.The American journal of case reports · 2025Article
- Comparison of Plasma Oxalate Measurement Methods in Patients With End-Stage Kidney Disease.Kidney international reports · 2025Article
- Metabolic dysfunction associated steatotic liver and kidney stones: what is going on?Current opinion in nephrology and hypertension · 2025Review
- Vitamin C in Cardiovascular Disease: From Molecular Mechanisms to Clinical Evidence and Therapeutic Applications.Antioxidants (Basel, Switzerland) · 2025Review
- Oxalate nephropathy from high-dose intravenous vitamin C in a patient with multiple myeloma.Journal of nephrology · 2025Article
- Application of Chitosan@FeSensors (Basel, Switzerland) · 2025Article
- A case report of renal oxalosis and secondary hyperoxaluria due to chronic high vitamin C consumption.Clinical nephrology. Case studies · 2025Article
- Purpuric rash after starting hemodialysis-not the immediate suspect: a case report and literature review.Frontiers in nephrology · 2025Article
- Primary Hyperoxaluria Screening and Monitoring: Quantitative Measurement of Plasma Oxalate by Gas Chromatography-Mass Spectrometry With High Sensitivity.Annals of laboratory medicine · 2024Article
- Oxalates: Dietary Oxalates and Kidney Inflammation: A Literature Review.Integrative medicine (Encinitas, Calif.) · 2024Review
- Progress in the Use of Hydrogels for Antioxidant Delivery in Skin Wounds.Pharmaceutics · 2024Review
- Oxalate nephropathy after pancreaticoduodenectomy: a case report.BMC nephrology · 2024Review
- Plasma metabolomics reveals risk factors for lung adenocarcinoma.Frontiers in oncology · 2024Article
- Review
- Oxalate (dys)Metabolism: Person-to-Person Variability, Kidney and Cardiometabolic Toxicity.Genes · 2023Review
- Oxalate Homeostasis in Non-Stone-Forming Chronic Kidney Disease: A Review of Key Findings and Perspectives.Biomedicines · 2023Review
- Analytical Methods for Oxalate Quantification: The Ubiquitous Organic Anion.Molecules (Basel, Switzerland) · 2023Review
- Secondary oxalate nephropathy and impact of high-dose vitamin C intake for COVID-19 prevention on a patient with Roux-en-Y gastric bypass: A case report.Clinical case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
In humans, approximately 60 mg of ascorbic acid (AA) breaks down in the body each day and has to be replaced by a dietary intake of 70 mg in women and 90 mg in men to maintain optimal health and AA homeostasis. The breakdown of AA is non-enzymatic and results in oxalate formation. The exact amount of oxalate formed has been difficult to ascertain primarily due to the limited availability of healthy human tissue for such research and the difficulty in measuring AA and its breakdown products. The breakdown of 60 mg of AA to oxalate could potentially result in the formation of up to 30 mg oxalate per day. This exceeds our estimates of the endogenous production of 10-25 mg oxalate per day, indicating that degradative pathways that do not form oxalate exist. In this review, we examine what is known about the pathways of AA metabolism and how oxalate forms. We further identify how gaps in our knowledge may be filled to more precisely determine the contribution of AA breakdown to oxalate production in humans. The use of stable isotopes of AA to directly assess the conversion of vitamin to oxalate should help fill this void.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.